Application of a colorimetric CTLL-2 cell proliferation assay for the evaluation of IL-15 antagonists

Biotecnologia Aplicada

Volumn 31, Issue 4, 2014, Pages 291-296

  Rodríguez Álvarez, Yunier ^a   Gerónimo Pérez, Haydee ^a   Garay Pérez, Hilda ^a   Castro Velazco, Jorge ^a   García Illera, Gerardo ^a   Santos Savio, Alicia ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Antagonist; CTLL 2 cell line; Interleukin 15; Peptide; Proliferation assay; Serum

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; P8 PEPTIDE; PEPTIDE VACCINE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; CELL PROLIFERATION ASSAY; COLORIMETRY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; HAPLORHINI; IC50; IMMUNE DYSREGULATION; MOUSE; NONHUMAN; REVIEW; VACCINATION;

MURINAE; MUS;

EID: 84938768946     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006;17(4):259-80.
2. Meazza R, Azzarone B, Orengo AM, Ferrini S. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol. 2011;2011:861920.
3. Kokaji AI, Hockley DL, Kane KP. IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells. J Immunol. 2008;180(7):4391-401.
4. Magyari L, Varszegi D, Kovesdi E, Sarlos P, Farago B, Javorhazy A, et al. Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. World J Orthop. 2014;5(4):516-36.
5. Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators of inflammation. 2014;2014:545493.
6. Yadav PK, Chen C, Liu Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J Biomed Biotechnol. 2011;2011:348530.
7. Harris KM, Fasano A, Mann DL. Monocytes differentiated with IL-15 support Th17 and Th1 responses to wheat gliadin: implications for celiac disease. Clin Immunol. 2010;135(3):430-9.
8. Rashtak S, Murray JA. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. 2012;35(7):768-81.
9. McLInnes IB. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha. Ernst Schering Res Found Workshop. 2006(56):29-44.
10. Patterson KC, Hogarth K, Husain AN, Sperling AI, Niewold TB. The clinical and immunologic features of pulmonary fibrosis in sarcoidosis. Transl Res. 2012;160(5):321-31.
11. Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikbeta1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013;121(3):476-84.
12. Ferrari-Lacraz S, Zheng XX, Kim YS, Li Y, Maslinski W, Li XC, et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol. 2001;167(6):3478-85.
13. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003;112(10):1571-80.
14. Tinubu SA, Hakimi J, Kondas JA, Bailon P, Familletti PC, Spence C, et al. Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival. J Immunol. 1994;153(9):4330-8.
15. Santos A, Cabrales A, Reyes O, Gerónimo H, Rodríguez Y, Garay H, et al. Identification of an interleukin-15 antagonist peptide that binds to IL-15Ra. Biotecnol Apl. 2008; 25:320-24.
16. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13(12):2822-30.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63.
18. Scherliess R. The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells. Int J Pharm. 2011;411(1-2):98-105.
19. Wright JF. Bioassays and biological stability. Dev Biol Stand. 1999;97:73-80.
20. Mire-Sluis AR, Gerrard T, Das RG, Padilla A, Thorpe R. Biological assays: their role in the development and quality control of recombinant biological medicinal products. Biologicals. 1996;24(4):351-62.
21. Mire-Sluis AR, Page L, Thorpe R. Quantitative cell line based bioassays for human cytokines. J Immunol Methods. 1995;187(2):191-9.
22. Santos A, Morera Y, Araña M, Ferrero J, Moro A, García J, et al. Obtaining Biologically Active IL-15 in Escherichia coli. Biotecnol Apl. 2000; 17: 221-224.
23. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995;14(15):3654-63.
24. Savio AS, Acosta OR, Perez HG, Alvarez YR, Chico A, Perez HG, et al. Enhancement of the inhibitory effect of an IL-15 antagonist peptide by alanine scanning. J Pept Sci. 2012;18(1):25-9.
25. Zagury D, Burny A, Gallo RC. Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines. Proc Natl Acad Sci USA. 2001;98(14):8024-9.
26. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492-503.
27. Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today. 2004;9(2):72-81.
28. Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy MK, Le T, et al. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine. 2002;20(3):121-9.